- Home
- LPRO vs VNDA Comparison
LPRO vs VNDA Comparison
Compare LPRO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- VNDA
- Stock Information
- Founded
- LPRO 2000
- VNDA 2002
- Country
- LPRO United States
- VNDA United States
- Employees
- LPRO N/A
- VNDA N/A
- Industry
- LPRO Finance: Consumer Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- VNDA Health Care
- Exchange
- LPRO Nasdaq
- VNDA Nasdaq
- Market Cap
- LPRO 252.9M
- VNDA 249.4M
- IPO Year
- LPRO N/A
- VNDA 2006
- Fundamental
- Price
- LPRO $1.80
- VNDA $5.54
- Analyst Decision
- LPRO Buy
- VNDA Strong Buy
- Analyst Count
- LPRO 6
- VNDA 2
- Target Price
- LPRO $3.00
- VNDA $16.50
- AVG Volume (30 Days)
- LPRO 660.9K
- VNDA 551.1K
- Earning Date
- LPRO 11-06-2025
- VNDA 10-29-2025
- Dividend Yield
- LPRO N/A
- VNDA N/A
- EPS Growth
- LPRO N/A
- VNDA N/A
- EPS
- LPRO N/A
- VNDA N/A
- Revenue
- LPRO $16,254,999.00
- VNDA $203,467,000.00
- Revenue This Year
- LPRO $306.78
- VNDA $15.45
- Revenue Next Year
- LPRO $11.69
- VNDA $37.82
- P/E Ratio
- LPRO N/A
- VNDA N/A
- Revenue Growth
- LPRO N/A
- VNDA 11.78
- 52 Week Low
- LPRO $0.70
- VNDA $3.81
- 52 Week High
- LPRO $6.92
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- LPRO 39.97
- VNDA 66.36
- Support Level
- LPRO $1.78
- VNDA $5.46
- Resistance Level
- LPRO $1.98
- VNDA $5.70
- Average True Range (ATR)
- LPRO 0.13
- VNDA 0.18
- MACD
- LPRO -0.01
- VNDA 0.01
- Stochastic Oscillator
- LPRO 15.28
- VNDA 81.36
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.